The MEK inhibitor cobimetinib was studied in combination with the PD-L1 inhibitor atezolizumab in the phase III trial IMblaze370 consisting of 363 metastatic colorectal cancer patients, 91.7% of whom had MSS or MSI-low tumors [106]. The gene discussed is CD274; the disease is metastatic colorectal cancer.